Table of Contents
Dr. Ines Fernandez Ulibarri
Helmholtz Group Oncolytic Adenoviruses, DKFZ (German Cancer Research Center)
Im Neuenheimer Feld 242
+49 (0)6221 42-4451
In-Vitro Evolution & Bioselection
Human adenoviruses are promising oncolytic agents which are restricted to cancer cells. However, pre-clinical and clinical trials have shown that overall therapeutic efficacy was insufficient due to a limited replication and spread of the virus in tumors. For that reason, my project is focused on developing a new methodology to generate efficient oncolytic adenoviruses to improve both efficacy and selectivity of cancer treatment. To this aim, I will combine two strategies: bioselection and genetic engineering in order to enhance the oncolytic activity and tumor - selectivity of adenoviruses. In the first step, we want to generate a highly diverse library of mutant viruses by inducing random mutations followed by bioselection of the most potent mutants. Next, to further ensure selectivity of the best mutants obtained, we will restrict the replication to target cancer cell by rational genetic engineering using tumor-specific promoters.